Velika Britanija -
angleščina -
MHRA (Medicines & Healthcare Products Regulatory Agency)
descovy 200mg10mg tablets
gilead sciences international ltd - tenofovir alafenamide fumarate; emtricitabine - tablet - 10mg ; 200mg
Velika Britanija -
angleščina -
MHRA (Medicines & Healthcare Products Regulatory Agency)
descovy 200mg25mg tablets
gilead sciences international ltd - tenofovir alafenamide fumarate; emtricitabine - tablet - 25mg ; 200mg
Velika Britanija -
angleščina -
MHRA (Medicines & Healthcare Products Regulatory Agency)
odefsey 200mg25mg25mg tablets
gilead sciences international ltd - tenofovir alafenamide fumarate; rilpivirine hydrochloride; emtricitabine - tablet - 25mg ; 25mg ; 200mg
Velika Britanija -
angleščina -
MHRA (Medicines & Healthcare Products Regulatory Agency)
epclusa 400mg100mg tablets
gilead sciences international ltd - sofosbuvir; velpatasvir - tablet - 400mg ; 100mg
Velika Britanija -
angleščina -
MHRA (Medicines & Healthcare Products Regulatory Agency)
zydelig 100mg tablets
gilead sciences international ltd - idelalisib - tablet - 100mg
Velika Britanija -
angleščina -
MHRA (Medicines & Healthcare Products Regulatory Agency)
zydelig 150mg tablets
gilead sciences international ltd - idelalisib - tablet - 150mg
Velika Britanija -
angleščina -
MHRA (Medicines & Healthcare Products Regulatory Agency)
vosevi 400mg100mg100mg tablets
gilead sciences international ltd - voxilaprevir; velpatasvir; sofosbuvir - tablet - 100mg ; 100mg ; 400mg
Evropska unija -
angleščina -
EMA (European Medicines Agency)
vosevi
gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitis c, chronic - antivirals for systemic use - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1).
Velika Britanija -
angleščina -
MHRA (Medicines & Healthcare Products Regulatory Agency)
vemlidy 25mg tablets
gilead sciences international ltd - tenofovir alafenamide fumarate - tablet - 25mg
Evropska unija -
angleščina -
EMA (European Medicines Agency)
veklury
gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19